Autonomix Medical (Nasdaq:AMIX) has tapped Medtronic’s former chief regulatory counsel, Sandra Cohen Kalter, for its board of directors as it looks to advance its pipeline of catheters for mapping and treating the nervous system. Kalter has served as an advisor to Autonomix’s board for nearly a year. Now with her own seat, the company hopes […]
MassDevice Medtronic Hub
Medtronic is the largest medical device company in the world, according to Medical Design & Outsourcing's MedTech Big 100.
The world’s largest medical device company has gotten its mojo back. Medtronic reported year-over-year revenue growth of 9.9% in the fourth quarter of its most recent fiscal year — its best quarterly revenue growth in 10 years — with sales for the full year up 8.4%. Needham & Co. analysts said at the time that they see Medtronic in the early stages of a strong product cycle that will drive faster organic revenue growth. AFib-treating cardiac ablation has been a standout performer, with strong commercial demand for the Affera Sphere-9 pulsed-field ablation (PFA) catheter. PFA could become even more of a success for Medtronic as the nitinol-enabled Affera Sphere-360, an all-in-one mapping and single-shot PFA catheter, launches in the EU, with a U.S. pivotal trial enrolling swiftly. On top of PFA, Medtronic officials are also excited about the growth potential of the company’s Symplicity Spyral renal denervation system for uncontrolled hypertension. The company is seeking expanded U.S. indications for its Hugo robotic surgery system as it takes on Intuitive in the soft-tissue surgical robotics space, and there’s excitement around the Altaviva implantable tibial neuromodulation for urge urinary incontinence and the Stealth AXiS robotic spine surgery system. Medtronic has also resumed mergers and acquisitions this year, announcing a string of purchases including $650 million for SPR Therapeutics and its percutaneous peripheral nerve stimulation therapies for chronic pain management, $550 million for Scientia Vascular and its products for treating complex neurovascular conditions, and $585 million for CathWorks and its FFRangio system meant to obtain quick and reliable fractional flow reserve. Said CEO Geoff Martha: “We executed our focused portfolio strategy. In early March, we completed the MiniMed [diabetes business] IPO, establishing it as a standalone, publicly traded [diabetes tech] company. We also advanced our M&A and venture initiatives, targeting higher growth segments to accelerate innovation in markets where we have a right to win.” – CN
Headquarters: Dublin, Ireland (Operational HQ in Fridley, Minnesota)
United States
Revenue ($USD): $36,364,000,000
R&D spend: $2,873,000,000
Employees: 101,369
Fiscal year end: 4/24/2026
CEO: Geoff Martha
Recent Medtronic News
Medtronic strengthens robotic surgery position with Cornerstone deal, analysts say
While some industry watchers have declared Medtronic’s (NYSE:MDT) recent marquee investment in Cornerstone Robotics a sign of wavering confidence in its homegrown Hugo platform, analysts say a closer look holds the potential of a broader customer base and stronger strategic position. In a note to investors, Needham & Co. analysts agreed with Medtronic’s pitch that […]
Mindray looks to fill hospital ventilator gap left by Philips’ exit
Mindray is rolling out a new model in its hospital ventilator lineup, following the exits of major medtechs in the respiratory care sector, including Philips and Medtronic. According to the company, the SV70 allows clinicians to switch between non-invasive ventilation and integrated high-flow oxygen therapy. The system is currently available in the U.S., with demonstrations […]
Medtronic grabs FDA clearance to add LigaSure vessel sealer to Hugo
Medtronic (NYSE: MDT) has received an FDA green light to bring its vessel-sealing technology over to its Hugo surgical robot, adding to the platform’s U.S. catalog of energy instruments. The agency’s clearance covers the first version of the LigaSure Maryland jaw device designed specifically for robotic-assisted surgery. According to Medtronic, the hand-held vessel sealer has […]
Medtronic hires former Recor CEO to run interventional cardiology group
Medtronic (NYSE:MDT) has hired former Recor Medical President and CEO Lara Barghout as president of the Interventional Cardiology Therapies (ICT) operating unit. The ICT business covers minimally invasive therapies in structural heart, coronary, and hypertension management, the last of which includes renal denervation (RDN). Watch on-demand: The 2026 MDO Min-Vasive Medtech webinar series Recor Medical won […]
Medtronic moves to divest final stake in MiniMed
Medtronic (NYSE: MDT) is entering the final stretch of its long-running plan to split from its diabetes technology business, with the launch of an exchange offer that will allow stockholders to swap their company shares for those of the independent MiniMed (Nasdaq: MMED). With its catalog of insulin pumps, continuous glucose monitors and other diabetes […]
Edwards Lifesciences, Medtronic score CMS win for TAVR
Edwards Lifesciences (NYSE: EW) and Medtronic (NYSE: MDT) are among the medtech companies praising CMS’s decision to expand Medicare coverage for TAVR to people with asymptomatic severe aortic stenosis. The finalized national coverage decision, published yesterday evening, also removes the evidence development (CED) requirement for symptomatic cases. In addition, CMS plans to review the evidence […]
Medtronic veteran joins Teleflex’s board
Teleflex (NYSE: TFX) announced today that it has appointed Sean Salmon to its board of directors. Salmon previously spent more than two decades at Medtronic before stepping down in September of 2025. He most recently served as EVP and president of the medtech giant’s Cardiovascular portfolio. Before that, he led both Cardiovascular and Diabetes as […]
Medtronic says Endurant stent graft’s new CE mark could boost use for ruptured AAA
Medtronic (NYSE: MDT) has secured a CE mark for its Endurant stent graft, removing a treatment warning related to its use in ruptured abdominal aortic aneurysms (AAA). The Minnesota-run medtech giant received a similar FDA labeling change in late 2025. A ruptured AAA occurs when the main artery in the abdomen bursts, causing severe internal […]
Medtronic invests $780M in two companies amid Street-beating Q2
Medtronic (NYSE: MDT) blew past Wall Street’s high expectations amid double-digit revenue growth, driven by strong demand for AFib-treating pulsed-field ablation (PFA) and more. “Q1 represents a strong start to fiscal ’27. … These results reinforce our confidence in the durability of our growth,” CEO Geoff Martha said during the Minnesota-run medtech giant’s earnings call […]
Medtronic recalls reflux testing system after 184 serious injuries
Medtronic initiated a global voluntary recall for certain lots of its Bravo calibration-free (CF) reflux testing system after reports of 184 serious injuries associated with a deployment control problem. Medtronic recalled the device “due to a risk of attachment and detachment issues related to the system’s delivery system,” a Medtronic spokesperson told MassDevice. “To ensure […]
